Symplekin, a polyadenylation factor, prevents MOZ and MLL activity on HOXA9 in hematopoietic cells

MOZ and MLL encoding a histone acetyltransferase and a histone methyltransferase, respectively, are targets for recurrent chromosomal translocations found in acute myeloblastic or lymphoblastic leukemia. We have previously shown that MOZ and MLL cooperate to activate HOXA9 gene expression in hematop...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biochimica et biophysica acta 2013-12, Vol.1833 (12), p.3054-3063
Hauptverfasser: Largeot, Anne, Paggetti, Jérôme, Broséus, Julien, Aucagne, Romain, Lagrange, Brice, Martin, Romain Z., Berthelet, Jean, Quéré, Ronan, Lucchi, Géraldine, Ducoroy, Patrick, Bastie, Jean-Noël, Delva, Laurent
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:MOZ and MLL encoding a histone acetyltransferase and a histone methyltransferase, respectively, are targets for recurrent chromosomal translocations found in acute myeloblastic or lymphoblastic leukemia. We have previously shown that MOZ and MLL cooperate to activate HOXA9 gene expression in hematopoietic stem/progenitors cells. To dissect the mechanism of action of this complex, we decided to identify new proteins interacting with MOZ. We found that the scaffold protein Symplekin that supports the assembly of polyadenylation machinery was identified by mass spectrometry. Symplekin interacts and co-localizes with both MOZ and MLL in immature hematopoietic cells. Its inhibition leads to a decrease of the HOXA9 protein level but not of Hoxa9 mRNA and to an over-recruitment of MOZ and MLL onto the HOXA9 promoter. Altogether, our results highlight the role of Symplekin in transcription repression involving a regulatory network between MOZ, MLL and Symplekin. •Symplekin interacts with MOZ and MLL on the HOXA9 promoter.•Symplekin affects HOXA9 protein levels.•Symplekin prevents MOZ and MLL recruitment on the HOXA9 promoter.
ISSN:0167-4889
0006-3002
1879-2596
DOI:10.1016/j.bbamcr.2013.08.013